CURANUM AG

EANS-Adhoc: Capital increase to accompany Curanum's follow-up financing

--------------------------------------------------------------------------------
  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
27.09.2012

In parallel with the follow-up financing for the borrower's note loan which is
shortly to be concluded, the Management and Supervisory boards of Curanum AG
have today passed a resolution to increase the company's share capital through
issuing up to 3,315,000 ordinary bearer shares, each with a notional interest in
the share capital of EUR 1.00 per share. To this end, the approved capital is to
be completely utilized from currently EUR 39,192,000 to up to EUR 42,507,000
through granting subscription rights to all shareholders against cash. With the
capital increase, not only is the operating business to be strengthened, but the
company is also to be enabled to implement its future concepts which are
oriented to further earnings improvement.

The new shares will be offered to shareholders in a 11.7:1 ratio, at a
subscription price of EUR 1.50 per share. The 405,102 treasury shares owned by
the company will not participate in the subscription offer. The subscription
offer will be published in the electronic Federal Gazette prospectively on
October 2, 2012. The subscription period is set to run from October 4, 2012
until October 18, 2012. The stock market listing and delivery of the new shares
to shareholders are planned to occur subsequently. 

The new shares are fully dividend-entitled for the 2012 financial year. The
subscription offer is directed exclusively to existing shareholders. There are
no plans to organize subscription rights trading. With the subscription offer,
the right is also to be granted exclusively to the company's shareholders to
acquire by way of oversubscription at the subscription price any new shares
which have not been subscribed for by other shareholders. Binding offers for
such oversubscriptions are to be submitted during the subscription period. If
the allocation of additional requested new shares to all shareholders proves
impossible due to high oversubscription demand, the company will decide at its
due discretion concerning the allocation while complying with the principle of
equal treatment. The new shares are to be admitted to trading on the Regulated
Market (Prime Standard) on the Frankfurt Stock Exchange, without the publication
of a securities prospectus.


Further inquiry note:
Caroline Lutz
Leitung Unternehmensentwicklung
Tel.: +49(0)89/ 24 20 65-0
E-Mail: ir@curanum.de

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


issuer:      CURANUM AG
             Engelbertstraße 23-25
             D-81241 München
phone:       +49 (0)89 242065 51
FAX:         +49 (0) 89 242065 10
mail:     info@curanum.de
WWW:      http://www.curanum.de
sector:      Healthcare Providers
ISIN:        DE0005240709
indexes:     CDAX, Classic All Share, Prime All Share
stockmarkets: free trade: Berlin, Hamburg, Düsseldorf, Stuttgart, regulated
             dealing: München, regulated dealing/prime standard: Frankfurt 
language:   English
 



Weitere Meldungen: CURANUM AG

Das könnte Sie auch interessieren: